

Repotrectinib TRIDENT-1

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Repotrectinib TRIDENT-1

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: FDA: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. EMA: Repotrectinib as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) who are TKI naïve.

Experimental Arm: Repotrectinib

Control Arm: Single arm



